Investment Thesis
CytomX is burning $25.5M annually in operating cash while generating only $10.3M in flat-growth revenue, resulting in -177.9% net margins and negative returns on both equity and assets. Although the strong balance sheet ($28.8M cash, minimal debt) provides ~13 months of runway at current burn rates, the company faces imminent pressure to achieve profitability, raise capital (potentially dilutive), or achieve major revenue inflection with no evidence of near-term improvement.
Strengths
- Fortress balance sheet with $319.9M equity and only $1.6M debt
- Minimal leverage (0.00x debt/equity) provides financial flexibility
- Excellent liquidity (10.38x current ratio) for near-term obligations
Risks
- Severe cash burn of $25.5M annually with only ~13 months of runway at current rate
- Zero revenue growth YoY despite operating losses exceeding revenue by 1.9x
- Operating margin of -191.8% indicates core business model not generating returns
- Negative ROE (-5.7%) and ROA (-5.1%) destroying shareholder and asset value
- Pharmaceutical sector maturity required but company shows minimal revenue generation capability
- Likely future capital raise or asset sale needed within 12-18 months
Key Metrics to Watch
- Quarterly cash burn trend and cash runway forecast
- Revenue growth inflection or major commercial milestone announcements
- Clinical pipeline progress and regulatory approval timelines
- Operating expense reduction initiatives or restructuring plans
- Capital raise announcements and dilution impact
Financial Metrics
Revenue
10.3M
Net Income
-18.2M
EPS (Diluted)
$0.00
Free Cash Flow
-25.5M
Total Assets
359.4M
Cash
28.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-191.8%
Net Margin
-177.9%
ROE
-5.7%
ROA
-5.1%
FCF Margin
-249.1%
Balance Sheet & Liquidity
Current Ratio
10.38x
Quick Ratio
10.38x
Debt/Equity
0.00x
Debt/Assets
11.0%
Interest Coverage
-95.50x
Long-term Debt
1.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T10:14:57.728959 |
Data as of: 2026-03-31 |
Powered by Claude AI